Chapter 5 – presentation guidance – Great Britain
Information on naming, presentation and packaging when submitting a notification of intent to market e-cigarette and vape products in Great Britain.
Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs)
Converting Parallel Distribution Notices (PDNs) to UK Parallel Import Licences (PILs)The UK has in place arrangements for the continued authorisation of medicinal products.Great BritainParallel Distribution Notices are no longer valid…
Squamous cell carcinoma (SCC) and different types of lymphomas occurring in the capsule around breast implants
The Medicines and Healthcare products Regulatory Agency (MHRA) are continuing to closely monitor for cases of SCC and other types of lymphoma and the published literature.
Access Consortium Good Manufacturing Practice (GMP) Statement
Good Manufacturing Practice (GMP) ensures that medicinal products are consistently produced and controlled to the quality standards appropriate to their intended use or as required for marketing authorisation.
Supplying investigational medicinal products to Northern Ireland
Supply of investigational medicinal productsIMPs can be supplied from Great Britain to Northern Ireland with a pragmatic approach to applying European Union (EU) rules on importation requirements. Apart from a…
